KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$0.36.

  • Recursion Pharmaceuticals' EPS (Basic) fell 588.24% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 1870.97%. This contributed to the annual value of -$1.69 for FY2024, which is 701.99% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' EPS (Basic) stood at -$0.36, which was down 588.24% from -$0.41 recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' EPS (Basic) ranged from a high of -$0.28 in Q3 2021 and a low of -$1.33 during Q1 2021
  • For the 5-year period, Recursion Pharmaceuticals' EPS (Basic) averaged around -$0.44, with its median value being -$0.38 (2022).
  • As far as peak fluctuations go, Recursion Pharmaceuticals' EPS (Basic) tumbled by 5647.06% in 2021, and later skyrocketed by 7518.8% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.39 in 2021, then increased by 23.08% to -$0.3 in 2022, then plummeted by 40.0% to -$0.42 in 2023, then plummeted by 55.34% to -$0.65 in 2024, then skyrocketed by 44.82% to -$0.36 in 2025.
  • Its EPS (Basic) was -$0.36 in Q3 2025, compared to -$0.41 in Q2 2025 and -$0.5 in Q1 2025.